A major paradigm shift was introduced by the 2019 ESC guidelines on diabetes, prediabetes and CVD, recommending SGLT-2i or GLP-1 RAs with proven CV benefits in patients with atherosclerotic cardiovascular disease (ASCVD) or high/very high CV risk irrespective of HbA1c level. In the perspective of empowering clinicians to integrate evidence-based therapies into practice, our webinar will address the current management of cardiometabolic risk and provide a vision for the future.
CHAIRMAN
FRANCESCO COSENTINO
Unit of Cardiology
Department of Medicine
Solna
Karolinska Institute & Karolinska University Hospital
Stockholm, Sweden